Treatment Patterns and Survival in Patients with Intermediate, Advanced, or Terminal Stage of Hepatocellular Carcinoma in France over the Period 2015-2017: A Real-Life Study
Table 6
Mortality risk (hazard ratio) in patients with IAT† HCC treated with sorafenib (in first line of systemic treatment) according to patient characteristics, HCC aetiology, and previous HCC treatments (median overall survival: 7.3 months; 95% CI: 7-7.7).
Variables
Number of patients
Adjusted hazard ratio
95% hazard ratio confidence limits
value
Age (years)
<40
52
REF
40-49
118
1.126
0.728
1.743
0.5930
50-59
807
1.243
0.847
1.822
0.2659
60-69
1,704
1.120
0.767
1.636
0.5572
70-79
1,515
1.143
0.782
1.67
0.4897
≥80
462
1.110
0.752
1.639
0.5990
Gender
Female
595
REF
Male
4,063
0.982
0.88
1.095
0.7400
History of HCC curative treatment or type of disease progression
Previous curative treatment
1,061
REF
No curative treatment (de novo IAT stage† at HCC diagnosis)
2,959
1.680
1.529
1.845
<.0001
Undetermined (lack of retrospective data)
638
1.349
1.189
1.531
<.0001
HCC aetiology (one answer only)
Viral hepatitis without alcohol‡
REF
Alcohol-related liver disease without viral hepatitis‡
1,949
1.027
0.916
1.151
0.6477
Alcohol-related liver disease and viral hepatitis‡
404
1.051
0.901
1.227
0.5258
Other liver diseases
268
1.122
0.943
1.335
0.1932
Metabolic risk factors only
833
1.145
1.004
1.307
0.0439
No identified liver disease or diabetes mellitus
522
0.947
0.817
1.099
0.4748
Previous TACE
No
3,579
REF
Yes
1,079
0.669
0.611
0.733
<.0001
†IAT: intermediate, advanced, or terminal stage; ‡with or without metabolic risk factors: NAFLD (nonalcoholic fatty liver disease), NASH (nonalcoholic steatohepatitis), or diabetes mellitus; TACE: transarterial chemoembolization.
